HUE058250T2 - Gyógyszer rhinovírus-fertõzés megelõzésére vagy kezelésére - Google Patents

Gyógyszer rhinovírus-fertõzés megelõzésére vagy kezelésére

Info

Publication number
HUE058250T2
HUE058250T2 HUE18833069A HUE18833069A HUE058250T2 HU E058250 T2 HUE058250 T2 HU E058250T2 HU E18833069 A HUE18833069 A HU E18833069A HU E18833069 A HUE18833069 A HU E18833069A HU E058250 T2 HUE058250 T2 HU E058250T2
Authority
HU
Hungary
Prior art keywords
medicament
prevention
treatment
rhinovirus infection
rhinovirus
Prior art date
Application number
HUE18833069A
Other languages
English (en)
Inventor
Johannes Stoeckl
Guido Gualdoni
Original Assignee
Univ Wien Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wien Med filed Critical Univ Wien Med
Publication of HUE058250T2 publication Critical patent/HUE058250T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE18833069A 2018-01-30 2018-12-28 Gyógyszer rhinovírus-fertõzés megelõzésére vagy kezelésére HUE058250T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18154088.1A EP3517117A1 (en) 2018-01-30 2018-01-30 Medicament for prevention or treatment of rhinovirus infection

Publications (1)

Publication Number Publication Date
HUE058250T2 true HUE058250T2 (hu) 2022-07-28

Family

ID=61094293

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18833069A HUE058250T2 (hu) 2018-01-30 2018-12-28 Gyógyszer rhinovírus-fertõzés megelõzésére vagy kezelésére

Country Status (13)

Country Link
US (2) US11413298B2 (hu)
EP (3) EP3517117A1 (hu)
JP (3) JP7359519B2 (hu)
CN (3) CN111655267B (hu)
AU (1) AU2018406914A1 (hu)
BR (1) BR112020012869A2 (hu)
CA (1) CA3086085A1 (hu)
EA (1) EA202091199A1 (hu)
ES (1) ES2907138T3 (hu)
HU (1) HUE058250T2 (hu)
PL (1) PL3634428T3 (hu)
PT (1) PT3634428T (hu)
WO (1) WO2019149436A1 (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515601A (zh) * 2020-03-16 2022-12-23 得克萨斯大学体系董事会 用己糖型单糖及其类似物治疗病毒感染的方法
WO2021205412A1 (en) * 2020-04-11 2021-10-14 Exploration Invest Pte Ltd 2-deoxy-d-glucose for prevention and treatment of a viral disease, in particular of covid-19
EP4188984A1 (en) 2020-07-30 2023-06-07 Ecole Polytechnique Federale De Lausanne (Epfl) Virucidal compositions and use thereof
WO2023062516A1 (en) * 2021-10-11 2023-04-20 Exploration Invest Pte Ltd 2-deoxy-d-glucose for use in disease therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2577321A (en) 1949-10-29 1951-12-04 Joseph B Filger Nose drop dispenser
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4603122A (en) * 1979-08-17 1986-07-29 Blough Herbert A Antiviral agent against herpes virus infections
EP0169146A3 (en) * 1984-07-20 1988-07-20 Merck & Co. Inc. Monoclonal antibodies directed against the cellular receptor of human rhinovirus
DE8422872U1 (de) 1984-08-01 1984-10-25 Anasco GmbH, 6200 Wiesbaden Spender zur intranasalen applikation von fluessigkeiten in form von sprays oder tropfen
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US6000580A (en) 1992-06-03 1999-12-14 Astra Aktielbolag Device for dispensing preservative-free nasal sprays and similar preparations
DE19706489C2 (de) * 1997-02-19 2000-08-31 Deutsches Krebsforsch Verwendung von 2-Desoxyglucose zur Behandlung von Human-Papilloma-Virus-assoziierten Läsionen und/oder Neoplasien
CA2238460A1 (en) * 1997-05-23 1998-11-23 Imutec Pharma Inc. Immunomodulating compositions for the treatment of viral disorders
US6260549B1 (en) 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
AU2003261475B2 (en) * 1998-11-05 2006-10-26 Centre National De La Recherche Scientifique Beta-L-2'-deoxy-nucleosides for the treatment of HIV infection
AU2002238801A1 (en) 2001-03-20 2002-10-03 Trudell Medical International Nebulizer apparatus and method
AU2008317374B2 (en) * 2007-10-23 2015-03-19 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding
CA2737146A1 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
US20100034839A1 (en) * 2008-07-25 2010-02-11 Martha Karen Newell Methods for treating viral disorders
BR112012009521B1 (pt) 2009-10-22 2021-07-13 Propanc Pty Ltd Composição farmacêutica e uso de quimotripsinogênio e tripsinogênio
CN102178686B (zh) * 2010-01-07 2016-01-13 王慧茹 多糖相关疾病的药物和疫苗及免疫测定产品
US8633165B2 (en) * 2010-08-04 2014-01-21 Wisconsin Alumni Research Foundation Neuroprotective effects of 2DG in traumatic brain injury
JP6043997B2 (ja) * 2010-12-08 2016-12-14 田中　信之 炎症性サイトカインの機能を抑制する炎症性疾患治療剤
EP3443964A1 (en) * 2011-11-23 2019-02-20 3B Pharmaceuticals, Inc. Antiviral formulations
WO2017023787A1 (en) * 2015-07-31 2017-02-09 The Johns Hopkins University Methods and compositions for treating metabolic reprogramming disorders
US10813893B2 (en) * 2017-02-24 2020-10-27 Cellular Sciences, Inc. Compositions and methods for the treatment and prevention of chronic hypoxemia and dyspnea

Also Published As

Publication number Publication date
CA3086085A1 (en) 2019-08-08
CN116459265A (zh) 2023-07-21
EP3634428A1 (en) 2020-04-15
JP2021516219A (ja) 2021-07-01
US20220362272A1 (en) 2022-11-17
CN111655267A (zh) 2020-09-11
EP3517117A1 (en) 2019-07-31
CN116473982A (zh) 2023-07-25
JP7359519B2 (ja) 2023-10-11
PL3634428T3 (pl) 2022-03-14
EP3634428B1 (en) 2022-01-26
BR112020012869A2 (pt) 2020-12-29
US20200397805A1 (en) 2020-12-24
ES2907138T3 (es) 2022-04-22
JP2023134592A (ja) 2023-09-27
WO2019149436A1 (en) 2019-08-08
EA202091199A1 (ru) 2020-10-19
PT3634428T (pt) 2022-03-22
JP2023134593A (ja) 2023-09-27
US11413298B2 (en) 2022-08-16
AU2018406914A1 (en) 2020-07-02
CN111655267B (zh) 2023-06-20
EP3988102A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
IL276398A (en) Combined treatment for mastocytosis
PL3634428T3 (pl) Lek do zapobiegania lub leczenia infekcji rinowirusowej
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
PT3558455T (pt) Cápsula ingerível para o tratamento fototerapêutico de infeções
SG11202008345RA (en) Fecal matter for prevention or treatment of autoimmune diseases
IL287904A (en) Combined treatment of arthritis
HK1257240A1 (zh) 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途
IL282643A (en) Soft combinations for the treatment of hematological diseases
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
GB201704688D0 (en) Calcicum based clinical material with antimicrobial properties and method of forming for prevention or treatment of infection
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
EP3789019A4 (en) Composition for prevention or treatment of skin infection
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
PL3431119T3 (pl) Aparat do pozaustrojowego oczyszczania krwi
GB201801466D0 (en) Preparation for treatment of wounds
PT3514235T (pt) Composição para o tratamento de um doente que sofre de colite ulcerosa, assim como utilização da composição como medicamento
SG11202110709QA (en) Pharmaceutical combination comprising trazodone for the treatment of neuropathic pain
IL275152A (en) System for hypothermia treatment of a patient
GB202111861D0 (en) Materials for the treatment of medical conditions
SG10201405850PA (en) Composition for prevention or treatment of urinary tract infection
EP3768681A4 (en) INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION
GB201814385D0 (en) Medical treatment of bone medicine processing system
GB201816621D0 (en) Prevention or treatment of adrenal insuffiency in critically ill patients
GB201904764D0 (en) Treatment of ophthalmological conditions